Comparisons Between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience
This retrospective study compared the outcomes in 32 adult patients with hematologic diseases (acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, severe aplastic anemia) who received allogeneic bone marrow transplantation (BMT, n = 14; median ag...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2003-11-01
|
Series: | Kaohsiung Journal of Medical Sciences |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1607551X09705042 |
id |
doaj-744a89770c5646ec8bfc7ec696589bb6 |
---|---|
record_format |
Article |
spelling |
doaj-744a89770c5646ec8bfc7ec696589bb62020-11-25T00:28:49ZengWileyKaohsiung Journal of Medical Sciences1607-551X2003-11-01191154154710.1016/S1607-551X(09)70504-2Comparisons Between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center ExperienceYi-Chang LiuChao-Sung ChangTa-Chih LiuTyen-Po ChenYu-Chieh SueHui-Hua HsiaoSheng-Fung LinThis retrospective study compared the outcomes in 32 adult patients with hematologic diseases (acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, severe aplastic anemia) who received allogeneic bone marrow transplantation (BMT, n = 14; median age, 28 years) or allogeneic peripheral blood stem cell transplantation (PBSCT, n = 18; median age, 29 years) from human leukocyte antigen-identical sibling donors. Median follow-up was 58 months in BMT recipients and 18 months in PBSCT recipients. Neutrophil (median, Day 8 vs Day 13, p < 0.001) and platelet engraftment (median, Day 9 vs Day 17, p < 0.001) was faster in the PBSCT group than in the BMT group. Patients receiving PBSCT required less platelet transfusion than those receiving BMT (median, 54 units vs 144 units, p < 0.001), but there was no significant difference in red cell transfusion. At 100 days, there was no difference in the incidence of acute graft-versus-host disease (GVHD) (42.9% vs 33.3%, p = 0.72) or grade II-IV acute GVHD (14.3% vs 5.6%, p = 0.57), and there was no difference in the cumulative incidence of chronic GVHD (20% vs 33.3%, p = 0.67). No chronic GVHD was noted in any relapsed patients (BMT, 5; PBSCT, 3), and no patients with chronic GVHD during follow-up had a relapse. Relapse was the most frequent cause of death in both groups (BMT, 5/9, 55.6%; PBSCT, 3/4, 75%; p = 0.25); all relapses occurred within 1 year after transplantation. Overall survival was significantly better in the PBSCT group (35.7% vs 77.8%, p = 0.029), but this difference was lost if only hematologic malignancies were analyzed (30.8% vs 63.6%, p = 0.20). Our results are similar to those reported previously, with faster neutrophil and platelet engraftment and less severe acute GVHD and extensive chronic GVHD with PBSCT. Allogeneic PBSCT is a feasible and beneficial alternative to allogeneic BMT in adult hematologic disease.http://www.sciencedirect.com/science/article/pii/S1607551X09705042allogeneicbone marrow transplantationperipheral blood stem cell transplantation |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yi-Chang Liu Chao-Sung Chang Ta-Chih Liu Tyen-Po Chen Yu-Chieh Sue Hui-Hua Hsiao Sheng-Fung Lin |
spellingShingle |
Yi-Chang Liu Chao-Sung Chang Ta-Chih Liu Tyen-Po Chen Yu-Chieh Sue Hui-Hua Hsiao Sheng-Fung Lin Comparisons Between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience Kaohsiung Journal of Medical Sciences allogeneic bone marrow transplantation peripheral blood stem cell transplantation |
author_facet |
Yi-Chang Liu Chao-Sung Chang Ta-Chih Liu Tyen-Po Chen Yu-Chieh Sue Hui-Hua Hsiao Sheng-Fung Lin |
author_sort |
Yi-Chang Liu |
title |
Comparisons Between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience |
title_short |
Comparisons Between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience |
title_full |
Comparisons Between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience |
title_fullStr |
Comparisons Between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience |
title_full_unstemmed |
Comparisons Between Allogeneic Peripheral Blood Stem Cell Transplantation and Allogeneic Bone Marrow Transplantation in Adult Hematologic Disease: A Single Center Experience |
title_sort |
comparisons between allogeneic peripheral blood stem cell transplantation and allogeneic bone marrow transplantation in adult hematologic disease: a single center experience |
publisher |
Wiley |
series |
Kaohsiung Journal of Medical Sciences |
issn |
1607-551X |
publishDate |
2003-11-01 |
description |
This retrospective study compared the outcomes in 32 adult patients with hematologic diseases (acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome, severe aplastic anemia) who received allogeneic bone marrow transplantation (BMT, n = 14; median age, 28 years) or allogeneic peripheral blood stem cell transplantation (PBSCT, n = 18; median age, 29 years) from human leukocyte antigen-identical sibling donors. Median follow-up was 58 months in BMT recipients and 18 months in PBSCT recipients. Neutrophil (median, Day 8 vs Day 13, p < 0.001) and platelet engraftment (median, Day 9 vs Day 17, p < 0.001) was faster in the PBSCT group than in the BMT group. Patients receiving PBSCT required less platelet transfusion than those receiving BMT (median, 54 units vs 144 units, p < 0.001), but there was no significant difference in red cell transfusion. At 100 days, there was no difference in the incidence of acute graft-versus-host disease (GVHD) (42.9% vs 33.3%, p = 0.72) or grade II-IV acute GVHD (14.3% vs 5.6%, p = 0.57), and there was no difference in the cumulative incidence of chronic GVHD (20% vs 33.3%, p = 0.67). No chronic GVHD was noted in any relapsed patients (BMT, 5; PBSCT, 3), and no patients with chronic GVHD during follow-up had a relapse. Relapse was the most frequent cause of death in both groups (BMT, 5/9, 55.6%; PBSCT, 3/4, 75%; p = 0.25); all relapses occurred within 1 year after transplantation. Overall survival was significantly better in the PBSCT group (35.7% vs 77.8%, p = 0.029), but this difference was lost if only hematologic malignancies were analyzed (30.8% vs 63.6%, p = 0.20). Our results are similar to those reported previously, with faster neutrophil and platelet engraftment and less severe acute GVHD and extensive chronic GVHD with PBSCT. Allogeneic PBSCT is a feasible and beneficial alternative to allogeneic BMT in adult hematologic disease. |
topic |
allogeneic bone marrow transplantation peripheral blood stem cell transplantation |
url |
http://www.sciencedirect.com/science/article/pii/S1607551X09705042 |
work_keys_str_mv |
AT yichangliu comparisonsbetweenallogeneicperipheralbloodstemcelltransplantationandallogeneicbonemarrowtransplantationinadulthematologicdiseaseasinglecenterexperience AT chaosungchang comparisonsbetweenallogeneicperipheralbloodstemcelltransplantationandallogeneicbonemarrowtransplantationinadulthematologicdiseaseasinglecenterexperience AT tachihliu comparisonsbetweenallogeneicperipheralbloodstemcelltransplantationandallogeneicbonemarrowtransplantationinadulthematologicdiseaseasinglecenterexperience AT tyenpochen comparisonsbetweenallogeneicperipheralbloodstemcelltransplantationandallogeneicbonemarrowtransplantationinadulthematologicdiseaseasinglecenterexperience AT yuchiehsue comparisonsbetweenallogeneicperipheralbloodstemcelltransplantationandallogeneicbonemarrowtransplantationinadulthematologicdiseaseasinglecenterexperience AT huihuahsiao comparisonsbetweenallogeneicperipheralbloodstemcelltransplantationandallogeneicbonemarrowtransplantationinadulthematologicdiseaseasinglecenterexperience AT shengfunglin comparisonsbetweenallogeneicperipheralbloodstemcelltransplantationandallogeneicbonemarrowtransplantationinadulthematologicdiseaseasinglecenterexperience |
_version_ |
1725334310466093056 |